NEW YORK (GenomeWeb News) – The chairman of the US Senate Judiciary Committee has asked National Institutes of Health Director Francis Collins to invoke a provision in federal law, which has never been used before, to license out Myriad Genetic's BRCA 1 and BRCA 2 gene patents.

Sen. Patrick Leahy (D-Vt.) last week sent a letter to Collins asking him to consider use of the so-called march-in rights under the Bayh-Dole Act "to ensure greater access to genetic testing for breast and ovarian cancer."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.